OncoMatch/Clinical Trials/NCT07082803
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Is NCT07082803 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including TLN-121 and TLN-254 for lymphoma.
Treatment: TLN-121 · TLN-254 · TLN-121 — The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
DLBCL, NOS, FL grade 3b, or transformed lymphoma from FL following at least 2 prior lines of therapy
Must have received: systemic therapy
FL grade 1-3a that requires treatment following at least 2 prior lines of therapy
Must have received: systemic treatment regimen
Peripheral T-cell lymphoma (PTCL) subtypes that have relapsed after, or not responded to at least 1 prior systemic treatment regimen
Must have received: systemic treatment regimen
High-Grade B-Cell Lymphoma that has relapsed after, or not responded to at least 2 prior systemic treatment regimens
Cannot have received: autologous stem cell transplantation
history of autologous stem cell transplantation within 60 days prior to the start of the study
Cannot have received: allogeneic stem cell transplantation
history of allogeneic stem cell transplantation within 90 days prior to the start of the study
Cannot have received: CAR T-cell or other T-cell targeting treatment
history of CAR T-cell or other T-cell targeting treatment ≤ 4 weeks prior to the start of the study
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford Medicine Cancer Center · Palo Alto, California
- The START Center for Cancer Care - Midwest · Grand Rapids, Michigan
- Washington University School of Medicine · St Louis, Missouri
- Memorial Sloan Kettering Cancer Center · New York, New York
- SCRI Oncology Partners · Nashville, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07082803 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous stem cell transplantation, allogeneic stem cell transplantation, CAR T-cell or other T-cell targeting treatment disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages